OMAHA, Neb. – Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions announced Wednesday that they are now dispensing Tezspire (tezepelumab), the first biologic to significantly reduce exacerbations in broad populations of patients with severe, uncontrolled asthma. Tezspire is a collaborative product, developed and manufactured by Amgen and AstraZeneca.
Asthma is a complex and heterogeneous disease affecting an estimated 339 million people worldwide. Approximately 10% of asthma patients have severe asthma. Globally, there are approximately 2.5 million severe asthma patients who are uncontrolled or biologic eligible, with approximately 1 million in the U.S. Patients with severe asthma have twice the risk of asthma-related hospitalizations. There is also a significant socio-economic burden, with these patients accounting for 50% of asthma-related health care costs.
Through this partnership, Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions high touch, whole-health service model will support asthma patients and providers throughout the country, including allergists, immunologists and pulmonologists. Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions, subsidiaries of Hy-Vee, Inc., have 21 locations throughout the U.S.
“When someone is having an asthma attack and struggling to breathe, every second counts. It is critical that severe asthma patients have life-saving medicine and resources readily available to them,” said Kristin Williams, president of Amber Specialty Pharmacy. “We are honored that Amgen and AstraZeneca recognize our passion for our patients. It is a privilege to take care of this population and help them safely navigate life with an asthma diagnosis.”